Pandion’s lead candidate PT101 has completed a phase 1a clinical trial backing its safety and tolerability, and is due to start a phase 1a/2b study in ulcerative colitis and a phase 2 trial in ...

as the Synthekine deal follows its earlier $1.9 billion takeover of Pandion Therapeutics, which is developing a pipeline of immune system modulators led by IL-2-based drug PT101. Merck has been on ...

Find out where and when this bird was seen. Subscribers can access more detailed information, including site specifics, a map and finder's comments. If you have a photo of this bird and would like it ...